Research programme: anti-methamphetamine therapies - InterveXion

Drug Profile

Research programme: anti-methamphetamine therapies - InterveXion

Alternative Names: ICKLH-SMO9; PCP-mAb

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arkansas for Medical Sciences
  • Developer InterveXion Therapeutics; University of Arkansas for Medical Sciences
  • Class Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Drug abuse

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Drug-abuse in USA (Parenteral)
  • 05 Apr 2016 Preclinical trials in Drug abuse (Prevention) in USA (Parenteral) (InterveXion Therapeutics Pipeline; April 2016), prior to April 2016
  • 29 May 2012 This programme is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top